Therapeutically interchangeable? A study of real‐world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 3, 2015-03 ,pp. : 245-253

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes

By Levin Philip   Wei Wenhui   Wang Li   Pan Chunshen   Douglas Damon   Baser Onur  

Current Medical Research and Opinion, Vol. 28, Iss. 3, 2012-03 ,pp. : 439-446

Informa Healthcare

Access to resources Recommend Favorite

Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy

By Davis Keith L.   Tangirala Muralikrishna   Meyers Juliana L.   Wei Wenhui  

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1083-1091

Informa Healthcare

Access to resources Recommend Favorite

Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies

By Xie Lin   Wei Wenhui   Pan Chunshen   Baser Onur  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1137-1145

Informa Healthcare

Access to resources Recommend Favorite

Effectiveness of vildagliptin as add‐on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real‐world setting

By  

JOURNAL OF DIABETES, Vol. 10, Iss. 1, 2018-01 ,pp. : 68-72

John Wiley & Sons Inc

Access to resources Recommend Favorite